Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus rating of “Buy” by the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $25.5714.

STOK has been the subject of a number of research reports. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a “buy” rating and a $30.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, July 1st. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the company a “buy” rating in a report on Monday, August 18th. Finally, Wedbush raised their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, August 13th.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 5,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the completion of the transaction, the insider owned 18,469 shares in the company, valued at $366,979.03. This trade represents a 22.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total transaction of $925,899.48. Following the transaction, the director owned 91,585 shares of the company’s stock, valued at approximately $1,843,606.05. The trade was a 33.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 160,180 shares of company stock worth $3,379,406 in the last quarter. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the period. GAMMA Investing LLC grew its position in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after buying an additional 5,084 shares during the period. Osaic Holdings Inc. grew its position in shares of Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after buying an additional 2,384 shares during the period.

Stoke Therapeutics Trading Up 1.9%

STOK opened at $27.31 on Wednesday. The company’s 50 day moving average is $19.94 and its 200-day moving average is $13.40. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $28.00. The company has a market cap of $1.50 billion, a P/E ratio of 32.13 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. On average, equities analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.